Company registration number 13480344 (England and Wales)
BIOZEN LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
BIOZEN LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
BIOZEN LIMITED
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
45,227
37,999
Current assets
Debtors
4
15,115
10,713
Cash at bank and in hand
6,878
21,762
21,993
32,475
Creditors: amounts falling due within one year
5
(28,896)
(26,733)
Net current (liabilities)/assets
(6,903)
5,742
Net assets
38,324
43,741
Capital and reserves
Called up share capital
2,046
2,046
Share premium account
131,992
131,992
Profit and loss reserves
(95,714)
(90,297)
Total equity
38,324
43,741

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 23 March 2026 and are signed on its behalf by:
Mr I Chaitowitz
Director
Company registration number 13480344 (England and Wales)
BIOZEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 2 -
1
Accounting policies
Company information

BioZen Limited is a private company limited by shares incorporated in England and Wales. The registered office is 25 Upper Park Road, Flat Four, London, NW3 2UN.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Capitalised Patent Development
over 17 years
1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

BIOZEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 3 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

BIOZEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -
1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
3
3
Intangible fixed assets
Capitalised Patent Development
£
Cost
At 1 July 2024
40,695
Additions
10,224
At 30 June 2025
50,919
Amortisation and impairment
At 1 July 2024
2,696
Amortisation charged for the year
2,996
At 30 June 2025
5,692
Carrying amount
At 30 June 2025
45,227
At 30 June 2024
37,999
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
15,115
10,713
BIOZEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 5 -
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
2,401
900
Other creditors
26,495
25,833
28,896
26,733
2025-06-30 2024-07-01 false false false CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr Chaitowitz Professor Brad Anawalt Mrs Anne Ezendam Professor Justin Stebbing Mr David Beadle Mr Richard Starr 13480344 2024-07-01 2025-06-30 13480344 2025-06-30 13480344 2024-06-30 13480344 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-06-30 13480344 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-06-30 13480344 core:CurrentFinancialInstruments 2025-06-30 13480344 core:CurrentFinancialInstruments 2024-06-30 13480344 core:ShareCapital 2025-06-30 13480344 core:ShareCapital 2024-06-30 13480344 core:SharePremium 2025-06-30 13480344 core:SharePremium 2024-06-30 13480344 core:RetainedEarningsAccumulatedLosses 2025-06-30 13480344 core:RetainedEarningsAccumulatedLosses 2024-06-30 13480344 bus:Director1 2024-07-01 2025-06-30 13480344 core:IntangibleAssetsOtherThanGoodwill 2024-07-01 2025-06-30 13480344 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-07-01 2025-06-30 13480344 2023-07-01 2024-06-30 13480344 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-06-30 13480344 core:CurrentFinancialInstruments core:WithinOneYear 2025-06-30 13480344 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 13480344 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 13480344 bus:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 13480344 bus:FRS102 2024-07-01 2025-06-30 13480344 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 13480344 bus:Director2 2024-07-01 2025-06-30 13480344 bus:Director3 2024-07-01 2025-06-30 13480344 bus:Director4 2024-07-01 2025-06-30 13480344 bus:Director5 2024-07-01 2025-06-30 13480344 bus:Director6 2024-07-01 2025-06-30 13480344 bus:FullAccounts 2024-07-01 2025-06-30 xbrli:pure xbrli:shares iso4217:GBP